Abstracts tagged "Vasculitis"

Abstract Number: 1416 • ACR Convergence 2020
Effects of the COVID-19 Pandemic on Patients Living with Vasculitis
Shubhasree Banerjee¹, Michael George², Kalen Young³, Shilpa Venkatachalam⁴, Jennifer Gordon⁵, Cristina Burroughs⁶, David Curtis⁷, Marcela Ferrada⁸, Kelly Gavigan⁹, Peter C. Grayson¹⁰, Joyce Kullman¹¹, Jeffrey R Curtis¹², Dianne Shaw³, William Nowell¹³ and Peter Merkel², ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³Vasculitis Foundation, Kansas City, ⁴Global Healthy Living Foundation, Upper Nyack, ⁵Temple University, Philadelphia, ⁶University of South Florida, Tampa, ⁷Global Healthy Living Foundation, New York City, ⁸Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁹Global Healthy Living Foundation, Upper Nyack, NY, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, ¹¹Vasculitis Foundation, Kansas City, MO, ¹²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹³Global Healthy Living Foundation, New York City, NY
Background/Purpose: The COVID-19 pandemic has the potential to impact how patients with vasculitis interact with health care systems due to concerns about infections. This study…
Abstract Number: 1638 • ACR Convergence 2020
Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients
David Martinez-Lopez¹, Lara Sanchez-Bilbao², Carmen Alvarez-Reguera², Alba Herrero Morant², Inigo Gonzalez-Mazon³, José Luis Martín-Varillas⁴, Guillermo Suarez-Amorin², Patricia Setien-Preciados², Cristina Mata-Arnaiz⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Sierrallana, Torrelavega, Spain, ⁵Hospital de Laredo, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and…
Abstract Number: 1943 • ACR Convergence 2020
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…
Abstract Number: 0414 • ACR Convergence 2020
Clinical Characteristics of an Internet-Based Cohort of Participants with a Self-Reported Diagnosis of Cryoglobulinemic Vasculitis or IgA Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Young⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹University of Kansas Medical Center, Overland Park, KS, ²David Geffen School of Medicine / University of California, Los Angeles, CA, ³Vasculitis Foundation, North Carolina, ⁴Vasculitis Foundation, Kansas City, ⁵University of South Florida, Tampa, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cyroglobulinemic vasculitis (CV) and IgA vasculitis are forms of small-vessel vasculitis characterized by immune complex deposition. The purpose of this study was to a)…
Abstract Number: 1420 • ACR Convergence 2020
Characterization of ANCA-Associated Vasculitis Among African American Patients
Sehris Khawaja¹, Saloni Godbole¹, Maryann Kimoto², Virginia Steen³ and Kaitlin Quinn⁴, ¹Georgetown University, Washington, DC, ²UCLA, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴National Institutes of Health, Washington, DC
Background/Purpose: ANCA-associated vasculitis (AAV) comprises a group of disorders characterized by inflammation of small and medium-sized arteries. Prevalence and phenotype of these diseases appear to…
Abstract Number: 1686 • ACR Convergence 2020
The COV-ASAKI Survey from the Pediatric Tuscany Network During COVID-19 Era
Maria Vincenza Mastrolia¹, Rino Agostiniani², Chiara Azzari³, Roberto Bernardini⁴, Ugo Bottone⁵, Giovanni Battista Calabri⁶, Flavio Civitelli⁷, Rita Consolini⁸, Roberto Danieli⁹, Rosalia Di Silvio¹⁰, Susanna Falorni¹¹, Luigi Gagliardi¹², Salvatore Grosso¹³, Marco Martini¹⁴, Graziano Memmini¹⁵, Marco Pezzati¹⁶, Giovanni Suriano¹⁷, Luca Tafi¹⁸, Angelina Vaccaro¹⁹, Pier Luigi Vasarri²⁰ and Gabriele Simonini²¹, ¹Rheumatology Unit, Meyer Children's University Hospital, Firenze, Italy, Florence, Toscana, Italy, ²Paediatric Unit, San Jacopo Hospital, Pistoia, Italy, Pistoia, Toscana, Italy, ³Paediatric Immunology Unit, Department of Health Sciences, Meyer Children’s University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁴Paediatric Unit, San Giuseppe Hospital, Empoli, Italy, Empoli, Toscana, Italy, ⁵Division of Neonatology and Pediatrics, Lotti Hospital, Pontedera, AUSL Toscana Nord Ovest, Pisa, Italy, Pisa, Toscana, Italy, ⁶Cardiologic Unit, Meyer Children’s University Hospital, Firenze, Italy, Florence, Toscana, Italy, ⁷Division of Neonatology and Pediatrics, Montepulciano Hospital, Montepulciano, AUSL Sud Est Toscana, Siena, Italy., Siena, Toscana, Italy, ⁸Section of clinical and laboratory Immunology, Department of clinical and experimental Medicine, University of Pisa, Italy, Pisa, Italy, ⁹Division of Neonatology and Pediatrics, Spedali Riuniti di Livorno, Livorno, AUSL Toscana Nord Ovest, Pisa, Italy, Livorno, Toscana, Italy, ¹⁰Paediatric Unit, Mugello Hospital, Borgo San Lorenzo, Firenze, Italy, Florence, Toscana, Italy, ¹¹Paediatric Unit, Misericordia Hospital, Grosseto, Italy, Grosseto, Italy, ¹²Division of Neonatology and Pediatrics, Ospedale Versilia Hospital, Viareggio, AUSL Toscana Nord Ovest, Pisa, Italy, Viareggio, Toscana, Italy, ¹³Clinical Pediatrics, Department of Molecular Medicine and Development, University of Siena, Siena, Italy, Siena, Toscana, Italy, ¹⁴Paediatric Unit, San Donato Hospital, Arezzo, Italy, Arezzo, Toscana, Italy, ¹⁵Division of Neonatology and Pediatrics, Apuane Hospital, Massa Carrara, AUSL Toscana Nord Ovest, Pisa, Italy, Massa Carrara, Toscana, Italy, ¹⁶Paediatric Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Firenze, Italy, Florence, Toscana, Italy, ¹⁷Division of Neonatology and Pediatrics, Cecina Hospital, Cecina, AUSL Toscana Nord Ovest, Pisa, Italy, Cecina, Toscana, Italy, ¹⁸Paediatric and Neonatal Unit, Valdarno Hospital, Montevarchi, Arezzo, Italy, Arezzo, Toscana, Italy, ¹⁹Division of Neonatology and Pediatrics, San Luca Hospital, Lucca, AUSL Toscana Nord Ovest, Pisa, Italy, Lucca, Toscana, Italy, ²⁰Paediatric and Neonatologic Unit, Santo Stefano Hospital, Prato, Italy, Prato, Toscana, Italy, ²¹Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: At the end of April 2020, national and international Pediatrics scientific societies diffused an alert about a rise in the number of pediatric severe,…
Abstract Number: 1945 • ACR Convergence 2020
Characterization of Visual Manifestations and Identification of Risk Factors for Permanent Vision Loss in Patients with Giant Cell Arteritis
Hussein Baalbaki¹, Darya Jalaledin², Catherine Lachance² and Jean-Paul Makhzoum³, ¹Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ²Universite de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Canadian Network for Research on Vasculitides (CanVasc), Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background/Purpose: Permanent vision loss (PVL) is a feared complication and a leading cause of morbidity in Giant Cell Arteritis (GCA). Multiple risk factors for ocular…
Abstract Number: 0415 • ACR Convergence 2020
Characteristics of Arthritis in Adult IgA Vasculitis
Alojzija Hocevar¹, Vesna Jurcic², Matija Tomsic¹ and Ziga Rotar¹, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia, ²Institute of Pathology, Medical Faculty, University of Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Arthritis is one of the main clinical features in IgA vasculitis (IgAV). In children, joint involvement represents the second most common manifestation with the…
Abstract Number: 1421 • ACR Convergence 2020
Clinical Features, Disease Activity and Prognosis of ANCA-Associated Vasculitis in US African Americans
Luis Palomino¹, Angelo Gaffo², Sebastian Sattui³ and Dongmei Sun², ¹University of Alabama at Birmingham Hospital, Birmingham, AL ²University of Alabama at Birmingham, Birmingham, AL, ³Hospital for Special Surgery, New York, NY
Background/Purpose: ANCA-associated vasculitis (AAV), including Granulomatosis with Polyangiitis (GPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Microscopic Polyangiitis (MPA), affect mostly Caucasians of European descent. Clinical…
Abstract Number: 1687 • ACR Convergence 2020
Kawasaki Disease Shock Syndrome in the Intensive Care Unit: A Single Center Cohort
Monica Bray¹, Jennifer Rammel², Andrea Ramirez¹, Kristen Sexson¹, Fong Lam¹, Eyal Muscal³ and Marietta DeGuzman³, ¹Baylor College of Medicine, Houston, TX, ²University of Florida Health Jacksonville, Jacksonville, FL, ³Baylor College of Medicine, Houston
Background/Purpose: Kawasaki disease (KD), a well described vasculitis of childhood, is the leading cause of acquired heart disease in developed countries. Kawasaki disease shock syndrome…
Abstract Number: 1946 • ACR Convergence 2020
Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Mark Matza¹, Minna Kohler², John H. Stone³ and Sebastian Unizony¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Fast-track clinics incorporating ultrasound into the initial evaluation of patients suspected of having giant cell arteritis (GCA) have been implemented throughout Europe leading to…
Abstract Number: 0424 • ACR Convergence 2020
Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis
Kristina Wells¹, Marcela Ferrada², Emily Rose², Keith Sikora³, Wendy Goodspeed², Kaitlin Quinn⁴ and Peter C. Grayson⁵, ¹Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, ²Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institutes of Health Clinical Center, Bethesda, MD, ⁴Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, ⁵Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are…
Abstract Number: 1422 • ACR Convergence 2020
Healthcare Utilization Among Patients Diagnosed with ANCA-Associated Vasculitis Between 2007 and 2014 in a Multi-Center Cohort Linked to Medicare Claims Data
Zachary Wallace¹, Xiaoqing Fu², John Stone³, Hyon Choi⁴ and Rochelle Walensky², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Concord, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: ANCA-associated vasculitis (AAV) leads to complications that contribute to poor quality of life and survival. Systemic vasculitis is associated with high healthcare utilization but…
Abstract Number: 1688 • ACR Convergence 2020
Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Cal Robinson¹, Francis Lao², Rahul Chanchlani¹, Anastasia Gayowsky³, Sandeep Brar⁴, Elizabeth Darling⁵, Catherine Demers⁵, Tapas Mondal¹, Rulan Parekh⁶, Hsien Seow⁵ and Michelle Batthish¹, ¹McMaster Children's Hospital, Hamilton, ON, Canada, ²Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada, ³ICES McMaster, Hamilton, ON, Canada, ⁴University of California, San Fransisco, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: The incidence of Kawasaki disease (KD) is increasing in Ontario. Cardiovascular sequelae following KD are well-described. However, there are limited and conflicting non-cardiovascular outcome…
Abstract Number: 1947 • ACR Convergence 2020
Risk Factors for Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis affecting patients aged above 50 years. Its clinical manifestations such as headache, jaw claudication…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].